Giulia Siravegna

Harvard University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

47h-index20.6kcitations311works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(169), Colorectal Cancer Treatments and Studies(152), Genetic factors in colorectal cancer(95), Lung Cancer Treatments and Mutations(74), Fibroblast Growth Factor Research(29)

Publications311 total

Data from Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
2024Open Access
Data from Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
2024Open Access
Supplementary Material 1 from Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
2024Open Access
Supplementary Material 1 from Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
2024Open Access
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Clinical Cancer Research·2024· 32 citedOpen Access
Liquid biopsy in oncology and tumor evolution
˜The œbiomedical & life sciences collection.·2024Open Access
Supplementary Table S1 from Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
2024Open Access
Supplementary Figure S1 from Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
2024Open Access
Supplementary Table S1 from Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
2024Open Access
Supplementary Table S2 from Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
2024Open Access
Supplementary Figure S1 from Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
2024Open Access
Data from Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
2024Open Access
Supplementary Table S2 from Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
2024Open Access
Data from Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
2024Open Access
Genomic analysis across 53 canine cancer types reveals novel mutations and high clinical actionability potential
Veterinary and Comparative Oncology·2023· 12 citedOpen Access
Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer
JAMA Network Open·2023· 8 citedOpen Access
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
Clinical Cancer Research·2023· 69 citedOpen Access
Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance
Frontiers in Oncology·2023· 1 citedOpen Access
Supplementary Figure S4 from Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
2023Open Access
Figure S1 and S2 from TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
2023Open Access
page 1 of 16Next →

Frequent Co-authors

Alberto Bardelli(39), Salvatore Siena(24), Andrea Sartore‐Bianchi(21), Federica Di Nicolantonio(19), Ryan B. Corcoran(16), Benedetta Mussolin(15), Emanuele Valtorta(13), Silvia Marsoni(12), Giovanni Crisafulli(12), Alessio Amatu(11), Giorgio Corti(10), Andrea Cassingena(10), Silvio Veronese(8), Michela Buscarino(8), Katia Bencardino(7), Giuseppe Rospo(7), Clara Montagut(7), Livio Trusolino(7), Alice Bartolini(7), Luca Lazzari(7)